Skip to main content
Fig. 4 | Molecular Neurodegeneration

Fig. 4

From: Modulation of GSK-3 provides cellular and functional neuroprotection in the rd10 mouse model of retinitis pigmentosa

Fig. 4

In vivo effect of short-term VP3.15 administration. rd10 mice received daily intraperitoneal injections of vehicle or VP3.15 from P15 to P21, and were analyzed one day after the last injection (P22). a-c and e RT-qPCR of WT as well as untreated rd10 retinas, and vehicle- and VP3.15-treated rd10 retinas (all harvested at P22). Levels of all transcripts were normalized to those of Tbp RNA and relativized to WT levels (= 1). Results represent the mean + SEM. n = 2–4, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, **** p ≤ 0.0001 (one-way ANOVA). d and f Representative images of P22 retinal sections from WT mice and from vehicle- and VP3.15-treated rd10 mice, immunostained for GFAP (d, red) and rhodopsin (f, cyan). Nuclei are stained with DAPI. In d arrows point to the radial processes of Müller cells and the arrow head to the most inner retinal layer containing the Müller end feet and astrocytes. Arrows in f point to mislocalized rhodopsin in the ONL. OS, outer segments; ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer. Scale bar: 60 μm

Back to article page